The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is a unique, longitudinal, observational cohort study of 241 autosomal dominant polycystic kidney disease (ADPKD) patients that began in 2000. The consortium consists of researchers at University of Alabama, University of Chicago, Emory University, University of Kansas Medical Center, Mayo Clinic, and University of Pittsburgh. The broad, long- term objectives of CRISP are to define the natural history of the disease and to discover prognostic biomarkers in early disease that can accurately predict long-term renal outcomes. The goals of CRISP IV are to continue follow-up of the CRISP cohort for 5 more years so as to refine models of CKD progression and strengthen the association between htTKV and renal outcomes, to validate disease models using existing and additional follow-up data from the HALT PKD study, and to incorporate powerful emerging imaging, genetic and biochemical biomarkers to improve the accuracy of prognostication for individual patients. To achieve this, the specific aims are:
Aim 1. Continue follow-up of CRISP and HALT participants. All CRISP participants that have not reached ESRD, together with HALT Study A participants followed at CRISP sites, will be followed up with annual serum creatinine measurements.
Aim 2. Develop improved models to predict GFR trajectories and progression to ESRD. Existing logistic regression and trajectory models will be refined and new approaches such as artificial neural network and classification tree models developed, using CRISP data for model fitting and HALT-A data for external validation.
Aim 3. Develop novel imaging, biochemical and genetic biomarkers of disease progression. Highly promising new biomarkers that are emerging from ancillary studies or being developed in parallel ongoing studies at the CRISP centers, will be evaluated for their ability to improve the accuracy of prognostic models.
The development and validation of prognostic biomarkers and models of disease progression that can predict, early in life, the subsequent loss of kidney function in ADPKD, will improve clinical care of these patients. It will enable interventional trials of therapy in patients prior to loss of kidney function, that ultimately may result in increased life expectancy and improved quality of life for patients with ADPKD.
|Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2017) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int :|